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ARTICLE
A two-stage association study identiﬁes methyl-CpG-
binding domain protein 2 gene polymorphisms as
candidates for breast cancer susceptibility
Yadav Sapkota1,2, Paula Robson3, Raymond Lai2,4, Carol E Cass1,4, John R Mackey1,4 and
Sambasivarao Damaraju*,1,2
Genome-wide association studies for breast cancer have identiﬁed over 40 single-nucleotide polymorphisms (SNPs), a subset of
which remains statistically signiﬁcant after genome-wide correction. Improved strategies for mining of genome-wide association
data have been suggested to address heritable component of genetic risk in breast cancer. In this study, we attempted a
two-stage association design using markers from a genome-wide study (stage 1, Affymetrix Human SNP 6.0 array, cases¼302,
controls¼321). We restricted our analysis to DNA repair/modiﬁcations/metabolism pathway related gene polymorphisms for their
obvious role in carcinogenesis in general and for their known protein–protein interactions vis-a `-vis, potential epistatic effects.
We selected 22 SNPs based on linkage disequilibrium patterns and high statistical signiﬁcance. Genotyping assays in
an independent replication study of 1178 cases and 1314 controls were attempted using Sequenom iPLEX Gold platform (stage
2). Six SNPs (rs8094493, rs4041245, rs7614, rs13250873, rs1556459 and rs2297381) showed consistent and statistically
signiﬁcant associations with breast cancer risk in both stages, with allelic odds ratios (and P-values) of 0.85 (0.0021), 0.86
(0.0026), 0.86 (0.0041), 1.17 (0.0043), 1.20 (0.0103) and 1.13 (0.0154), respectively, in combined analysis (N¼3115).
Of these, three polymorphisms were located in methyl-CpG-binding domain protein 2 gene regions and were in strong linkage
disequilibrium. The remaining three SNPs were in proximity to RAD21 homolog (S. pombe), O-6-methylguanine-DNA
methyltransferase and RNA polymerase II-associated protein 1. The identiﬁed markers may be relevant to breast cancer
susceptibility in populations if these ﬁndings are conﬁrmed in independent cohorts.
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INTRODUCTION
Breast cancer is a multi-factorial, polygenic disease resulting from the
interplay of genetic, environmental and lifestyle risk factors. Linkage
studies have revealed that breast cancer tends to cluster in families and
disease prevalence is two-fold higher among the ﬁrst-degree relatives
of affected individuals.1 Familial clustering is characterized by early
onset of disease often mediated by high-to-moderate penetrance
mutations in genes, such as those encoding breast cancer (BRCA1
and BRCA2),2,3 ataxia telangiectasia mutated (ATM),4 cell cycle
checkpoint kinase 2 (CHEK2),5 tumor protein 53 (TP53),6 partner
and localizer of BRCA2,7 BRCA1-interacting protein C-terminal heli-
case 1 (BRIP1)8 and phosphatase and tensin homolog (PTEN).9
Nonetheless, these genes in aggregate account for o25% of the
observed familial genetic risk.10 A polygenic model has been proposed
to explain the remaining genetic risk in non-BRCA familial and
sporadic breast cancer cases.11 Single-nucleotide polymorphisms
(SNPs)-based genome-wide association studies (GWAS) have identi-
ﬁed low-risk conferring common variants in several complex diseases.
For European, Ashkenazi Jewish and Asian population-based GWAS,
more than 40 breast cancer susceptibility loci in several genes and
intergenic regions have already been reported and a subset of these
associations have reached genome-wide signiﬁcance level.12–14 These
variants account for a small proportion of overall genetic risk of breast
cancer, leaving open the question of hidden or missing heritability.
Current debates suggest that this may be further explained by rare
variants, epistasis, epigenetics, gene–environment interactions and
copy number variations.15,16
In a typical GWAS, the frequencies for each SNP (single-locus tests
for association)17 are compared between cases and controls to cata-
logue polymorphisms potentially associated with the phenotype of
interest. The most promising SNPs, sorted based on P-value ranking
(highest signiﬁcance) and/or showing signiﬁcance in haplotype asso-
ciation analysis,18 are selected and replicated in a larger but indepen-
dent set of cases and controls. In this process, SNPs that are not top
ranked because of their modest P-values are ignored, and as a result
potentially informative markers may have been missed. It has been
proposed by others19,20 that even modest associations (P-value based),
if highly reproducible in independent cohorts, may still be pertinent to
the phenotypes under investigation presumably through epistatic
interactions (interactions of alleles or genes), a phenomenon strongly
implicated in the etiology of breast cancer and the heritable compo-
nent of genetic risk. Because the majority of the published GWAS
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susceptibility loci, a candidate gene approach restricted to speciﬁc
pathway related gene polymorphisms to more effectively mine GWAS
data is presented considering moderately associated SNPs. If repro-
duced in further independent studies, these may serve as putative
candidates for epistatic effects.
Previously reported studies focused on common variants in the
genes involved in DNA repair/metabolism pathways and cell cycle
regulation, and the markers were selected based on candidate gene
approaches.21,22 In this study, we extend this premise using SNPs in or
ﬂanking the DNA repair, modiﬁcations and metabolism pathway-
related genes from the Affymetrix 6.0 array (Santa Clara, CA, USA)
(stage 1 of GWAS23) for independent replication, stage 2 of the
association study design) to identify additional breast cancer suscept-
ibility loci not previously reported.
MATERIALS AND METHODS
Study population and DNA isolation
We used stage 1 results of our published breast cancer GWAS, described
elsewhere.23 Brieﬂy, sporadic breast cancer cases (n¼348), characterized by late
onset of disease and controls (n¼348) who had no documented history of
breast cancer in the ﬁrst- and second-degree relatives were selected for stage 1
of the GWAS.23 All subjects were predominantly of Caucasian origin. Breast
cancer cases (median age¼51 years; age range¼26–90 years, with number of
cases o40 years¼35; 40–60 years¼241; 460 years¼72) were from Alberta,
Canada, recruited by the PolyomX Program24 and the Canadian Breast Cancer
Foundation-Tumor Bank, (CBCF-TB)24 during the years 2001–2005 and since
2005–2008, respectively. The two projects PolyomX Program and CBCF-TB are
funded by different granting agencies, and nomenclature adopted merely
indicates this and in no way reﬂects bias in sampling of population. All cases
had a histologically conﬁrmed diagnosis of invasive ductal breast carcinoma at
the time of enrolment in the study. Gender-matched apparently healthy
controls (median age¼50 years; age range¼36–70 years, with number of
controls o40 years¼50; 40–60 years¼226; 460 years¼72), also from Alberta,
Canada (accessed from the Tomorrow Project25), were frequency matched to
cases based on age. The proportions of cases and controls for three different age
groups (o40, 40–60 and 460 years) were not statistically signiﬁcant (two
tailed z-test; data not shown). All control subjects’ enrolled here were free from
cancer at the time of recruitment in the study. Potential population confoun-
ders were removed, leaving cases (n¼302) and controls (n¼321) for association
analysis.23 Informed consents were obtained from all study participants, and
the study was approved by Research Ethics Board of Alberta Health Services.
Genomic DNA was extracted from the peripheral blood samples of both cases
and controls using commercially available Qiagen (Mississauga, ON, Canada)
DNA isolation kits.
SNP selection, genotyping and platform-speciﬁc genotype
concordance
Data ﬁltering and call rate clean up (Hardy–Weinberg equilibrium (HWE)
P40.001 and SNPs call rate 499%) were carried out as described earlier.23 Of
the 906600 SNPs genotyped using Affymetrix SNP 6.0, a total of 782838 SNPs
qualiﬁed for the downstream analysis. The associations of SNPs with breast
cancer were evaluated using correlation/trend tests with one degree of freedom
(df). Correlation/trend test is similar to w2-test of independence, except that it
is also believed to be a trend test that evaluates correlation of a minor allele with
the case status using Pearson’s correlation coefﬁcient. The allelic tests with
782838 SNPs (stage 1) showed that a total of 35519 SNPs statistically
signiﬁcantly associated with breast cancer at Po0.05. Of the 35519 SNPs, we
identiﬁed 215 polymorphisms (minor allele frequency (MAF)410%) within or
in close proximity to 49 gene regions implicated in pathways or of relevance to
DNA repair, modiﬁcations and metabolism based on National Center for
Biotechnology Information human genome build 37. In all, six of 215 SNPs
were statistically signiﬁcantly associated with breast cancer at Po0.001 (corre-
lation/trend tests with one df) and were included for stage 2 replication study.
To reduce the redundancy among the remaining 209 SNPs, we then calculated
the pairwise LD (r2) among the markers and found that 73 SNPs were strongly
correlated (r2Z0.8). Of these 73 short-listed SNPs, 16 were in strong LD
(r2Z0.8), with at least one SNP contained within the identiﬁed 3903 haplotype
blocks (Po0.05) in haplotype association analysis. All haplotypes at a
frequency threshold of 1% or more were tested together against the reference
haplotype for their associations with breast cancer. The haplotype association
analysis per se was carried out as described elsewhere.23 As our primary
objective in this study was to evaluate the moderately associated SNPs from
stage 1 GWAS results, we relaxed the signiﬁcance threshold in haplotype asso-
ciation analysis to Po0.05 as compared with our previous study (Po0.001).23
Overall, we used allelic tests and haplotype association tests to select SNPs for
replication study in an independent set of 1178 invasive breast cancer cases and
1314 apparently healthy individuals serving as controls (stage 2).
Genotyping assays were performed on Sequenom iPLEX Gold platform
(San Diego, CA, USA) (services from the McGill University, Genome Quebec
Innovation Center, Montreal, Canada). Within- (Sequenom only) and
cross-platform (Affymetrix vs Sequenom) SNP concordances for 22 SNPs were
assessed using 205 and 551 duplicate samples, respectively.
Statistical considerations
Allelic associations were evaluated using correlation/trend tests with one df, and
their corresponding odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
estimated using unconditional logistic regression implemented in the SNP &
Variation Suite v7.3.1 (Helix Tree Software).26 Genotypic associations were also
considered for gaining insights in to relative contributions from individual
genotypes to breast cancer risk using unconditional logistic regression with two
df using the freeware, SNPstats,27 and the results from codominant models
were summarized in the study. A combined analysis with all samples from
stages 1 and 2 (a total of 1480 cases and 1635 controls) was performed to
increase the statistical power. The associations for the allelic tests in combined
analysis were further examined with 1000-times permutation tests and false
discovery rates (FDRs) to identify observations by chance alone (type 1 error)
using Helix Tree software. Helix Tree calculates FDR using the original P-value
times the number of tests divided by the number of tests minus the rank order
of the original P-value in the descending order.
Subgroup analyses were attempted (correlation/trend tests with 1 df) to
identify associations with subphenotypes within the combined breast cancer
cases using a common reference (combined controls) as described previously.28
The subphenotypes examined were family history of breast cancer, menopausal
status and luminal A status. Subgroup analyses help interrogate potential
confounding inﬂuence of disease heterogeneity on the observed associations.
Tumors were classiﬁed as luminal A based on estrogen and progesterone
receptor status (ER+/PR+,E R  /PR+ and ER+/PR ) and human epidermal
growth factor receptor-2 status (HER2 ).29 All the remaining cases were
classiﬁed as non-luminal A tumors.
Our sample size conferred more than 80% power to detect associations
using a codominant model for a SNP with 10% MAF, disease prevalence at 1/10
in population for breast cancer, a relative risk of 1.3, type I error of 0.05 and
with the LD between markers at r2 of 0.8.30
The LDpatterns for regions showing the strongest and consistent associations
across stages 1 and 2 and combined analyses were examined using Haploview
v4.2.31 For the three methyl-CpG-binding domain protein 2 (MBD2)S N P s ,
haplotype frequencies were estimated using SNPstats.27 The software imple-
ments the expectation-maximization algorithm coded into haplo.stats package
to calculate the estimated relative frequencies for each haplotype.32 Haplotype
association analyses for MBD2 SNPs were performed with unconditional logistic
regression using the default setting of a log-additive model and expressed in
terms of ORs and 95% CIs (feature available in SNPstats).
RESULTS
Initial assessment of the data quality
Of the 22 SNPs selected for replication in stage 2, genotyping for one
SNP (rs17519016) was not successful. The cross-platform (Affymetrix
vs Sequenom) SNP call concordance for the remaining 21 SNPs
using 551 duplicate samples from stage 1 was more than 98%.
Within-platform (Sequenom) SNP call concordance among the 205
CpG-binding proteins and breast cancer risk
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European Journal of Human Geneticsduplicates used in stage 2 was more than 99.4%. Per sample and per
SNP call rates for stage 2 were 498.3 and 498.4%, respectively, and
all 21 SNPs were in HWE proportion at P40.001 in controls
(Table 1). Cross-platform and within-platform discordances were
very low (o2%) and are in agreement with previously reported
GWAS studies.12,23 Further, the MAFs were consistent among the
two stages and also comparable to HapMap Central Europeans (CEU)
population (data not shown), indicating that the scope of false-
positive associations due to genotyping errors (systematic or random)
was effectively minimized.
Stage 2 analysis
In stage 2, six SNPs showed suggestive associations with breast cancer
(Table 2). Three SNPs (rs8094493, rs4041245 and rs7614) were from
MBD2 gene regions and were marginally associated with reduced risk
for breast cancer (ORs: 0.90, 0.91 and 0.92, respectively; Table 2). The
other three SNPs rs13250873, rs1556459 and rs2297381 were located
in or close proximity of RAD21 homolog (S. pombe; RAD21), O-6-
methylguanine-DNA methyltransferase (MGMT) and RNA polymer-
ase II-associated protein 1 (RPAP1) gene regions, respectively, and
showed suggestive associations with increased risk for breast cancer.
The association test results for the remaining 15 SNPs are summar-
ized in Supplementary Table 1. Fourteen of these showed no statistical
signiﬁcance and one SNP (rs7636114) showed suggestive association
trend in stage 2 (but in opposite direction to the stage 1 results) and is
therefore not considered for further analysis.
Combined analysis (stages 1 and 2)
We combined the results for six SNPs from stages 1 and 2, and
conducted a combined analysis and found not only similar direction
of risk but also stronger association signals for all six variants
(Table 2). The MBD2 SNPs rs8094493 (OR: 0.85, Po0.0021),
rs4041245 (OR: 0.86, Po0.0026) and rs7614 (OR: 0.86, Po0.0041)
were signiﬁcantly associated with reduced risk of breast cancer. The
observed FDR of 0.045, 0.027 and 0.029, respectively, for the allelic
associations in combined analysis provided conﬁdence in the study
ﬁndings. We also subjected the data to permutation testing (1000
times) and observed permutation P-values of 0.038, 0.048 and 0.069,
respectively, an indication that the reported ﬁndings may not be
attributed to associations by chance alone. The heterozygote and
variant homozygote genotypes of MBD2 SNPs from codominant
models also conferred similar trends of reduced risks of breast cancer
(ORs: 0.76–0.79).
The remaining polymorphisms analyzed (rs13250873, rs1556459
and rs2297381, Table 2) also showed signiﬁcant associations, except
the direction of risk for breast cancer (allelic ORs: 1.13–1.20) was in
opposite direction to the ones observed for MBD2 SNPs. The
association signals for all three SNPs were characterized by low FDR
values (0.023–0.054); the 1000-times permutation tests also showed
marginal signiﬁcance for rs13250873. In the codominant genotypic
models, variant homozygotes (ORZ1.28) showed stronger associa-
tions than heterozygotes (OR: 1.07–1.14) in the combined analysis for
rs13250873, rs1556459 and rs2297381.
Subgroup analyses
Owing to potential for genetic risk determinants to be associated with
speciﬁc clinical and molecular subtypes of breast cancer, we reviewed
clinicopathological characteristics of the cases in both stages 1 and 2,
and conducted stratiﬁed analyses (Table 3). We evaluated allelic
associations for six SNPs with the following subgroups: without and
Table 2 Six SNPs with the strongest and consistent associations with breast cancer susceptibility across stages 1, 2 and in combined analysis
Stage 1a Stage 2 b Stages 1+2 (combined analysis)c
SNPs Allele or genotype OR, 95% CI P-valued OR, 95% CI P-valued OR, 95% CI P-valued FDR
Permutation
P-valuee
rs8094493 G (minor allele) 0.68 (0.54, 0.85) 0.0009 0.90 (0.81, 1.01) 0.0773 0.85 (0.77, 0.94) 0.0021 0.045 0.038
GT 0.66 (0.46, 0.94) 0.0044 0.80 (0.67, 0.95) 0.0410 0.77 (0.66, 0.90) 0.0019 ND ND
GG 0.48 (0.31, 0.77) 0.86 (0.68, 1.09) 0.76 (0.61, 0.94) ND ND
rs4041245 G (minor allele) 0.68 (0.54, 0.85) 0.0009 0.91 (0.81, 1.02) 0.0893 0.86 (0.77, 0.95) 0.0026 0.027 0.048
GA 0.66 (0.46, 0.94) 0.0044 0.79 (0.67, 0.94) 0.0340 0.76 (0.65, 0.89) 0.0018 ND ND
GG 0.48 (0.31, 0.77) 0.87 (0.69, 1.10) 0.77 (0.62, 0.95) ND ND
rs7614 C (minor allele) 0.67 (0.54, 0.84) 0.0006 0.92 (0.82, 1.03) 0.1356 0.86 (0.78, 0.95) 0.0041 0.029 0.069
CT 0.70 (0.49, 0.99) 0.0038 0.81 (0.68, 0.97) 0.0690 0.79 (0.67, 0.92) 0.0053 ND ND
CC 0.47 (0.30, 0.74) 0.89 (0.70, 1.12) 0.77 (0.63, 0.95) ND ND
rs13250873 G (minor allele) 1.29 (1.01, 1.64) 0.0383 1.14 (1.01, 1.28) 0.0306 1.17 (1.05, 1.30) 0.0043 0.023 0.07
GA 1.34 (0.96, 1.87) 0.1100 1.10 (0.93, 1.30) 0.0910 1.14 (0.98, 1.33) 0.0190 ND ND
GG 1.56 (0.91, 2.68) 1.33 (1.02, 1.73) 1.37 (1.08, 1.74) ND ND
rs1556459 C (minor allele) 1.50 (1.10, 2.04) 0.0102 1.13 (0.97, 1.32) 0.1151 1.20 (1.04, 1.37) 0.0103 0.043 0.161
CT 1.49 (1.03, 2.14) 0.0390 1.05 (0.88, 1.26) 0.0740 1.13 (0.96, 1.32) 0.0120 ND ND
CC 2.21 (0.80, 6.07) 1.89 (1.07, 3.32) 1.96 (1.20, 3.20) ND ND
rs2297381 G (minor allele) 1.27 (1.01, 1.58) 0.0368 1.10 (0.98, 1.23) 0.0986 1.13 (1.02, 1.25) 0.0154 0.054 0.234
GA 1.28 (0.87, 1.89) 0.1100 1.02 (0.85, 1.24) 0.1800 1.07 (0.90, 1.27) 0.0430 ND ND
GG 1.60 (1.03, 2.50) 1.21 (0.97, 1.50) 1.28 (1.05, 1.55) ND ND
Abbreviations: CI, conﬁdence interval; FDR, false discovery rate; ND, not determined; OR, odds ratio.
a302 cases and 321 controls.
b1178 cases and 1314 controls.
c1480 cases and 1635 controls.
dIndividual P-values across stages and combined analysis are indicated. P-values for minor allele were calculated using the correlation/trend test with one df, whereas the P-values for the
heterozygote and variant genotypes (codominant genotypic model) were calculated using unconditional logistic regression with two df; FDR for observed associations in combined analysis using
allelic association tests.
e1000-times permutation P-value for observed associations in combined analysis using allelic association tests; P-values shown in bold indicate the combined analysis from allelic association tests.
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European Journal of Human Geneticswith family history of breast cancer, pre- and postmenopausal status
and luminal A and non-luminal A (ie, good and poor prognostic
groups, respectively) breast cancer status of the tumors, using correla-
tion/trend tests with one df. We found associations between clinico-
pathological characteristics and the polymorphisms considered, and
the observed ORs were consistent across subgroups (Table 3). None of
the observed associations were stronger than the single-locus effects,
and hence it is less likely that these clinicopathological characteristics
(potential confounders) have signiﬁcant effects on initial observed
associations with unstratiﬁed cases (Table 2).
Pairwise LD proﬁling between markers
We examined LD proﬁles for the six identiﬁed variants (Table 2)
using HapMap CEU genotype data (available from http://www.
hapmap.org). We found that three MBD2 SNPs (rs8094493,
rs4041245 and rs7614) in intron 3, intron 6 and the 3¢-untranslated
region, respectively, were in strong LD with D¢¼1 (Figure 1a), and
these proﬁles were also observed in our study population (Figure 1b).
rs7614 and rs4041245 were located in a LD block spanning B6kb
region, and rs8094493 was located in a LD block of B9kb region.
We also analyzed the remaining three SNPs (rs13250873, rs2297381
and rs1556459) that were associated with breast cancer in our study
population (Table 2) and found that these SNPs belong to different
blocks/regions and were not correlated with each other (data not
shown). The LD blocks containing rs13250873 and rs1556459 did not
show annotated genes. However, we observed UTP23 (B19kb down-
stream) and RAD21 (B52kbp downstream) as the nearest genes
ﬂanking rs13250873 and for rs1556459, the closet gene was MGMT
at B450kb upstream. On the other hand, the polymorphism
rs2297381 was located in intron 5 of RPAP1 gene.
Haplotype analysis for MBD2 gene polymorphisms
We reasoned that the highly correlated SNPs from the MBD2 gene
region may form distinct haplotypes that could potentially explain the
population diversity. Polymorphisms rs8094493, rs4041245 and
rs7614 formed two major haplotypes, one with common alleles
(major allele) and other with variant alleles (minor allele). The
common haplotype had a population frequency of 0.58 (0.60 for
cases and 0.56 for controls), and the variant haplotype had a popula-
tion frequency of 0.40 (0.38 for cases and 0.42 for controls). The
variant form was signiﬁcantly associated with the reduced risk of
breast cancer (OR: 0.86, Po0.0029; Table 4). The population diversity
that could be explained by the two major haplotypes identiﬁed in this
analysis was 98%.
DISCUSSION
In this study, we identiﬁed SNPs associated with breast cancer among
genes related to DNA repair, modiﬁcations and metabolism. A total of
six loci were identiﬁed using a two-stage association study design, and
these were not previously reported in published GWAS for breast
cancer12–14,23 as putative markers for breast cancer susceptibility.
The identiﬁed loci were highly reproducible in an independent study
(stage 2), and the statistical signiﬁcance of the ﬁndings was consistent
across study stages, in the combined analysis and across clinicopatho-
logical subtypes of breast cancer. These loci are promising markers and
warrant independent validation in Caucasian population or in diverse
ethnic cohorts to evaluate the generalizability of our ﬁndings.
The six loci identiﬁed were from four chromosomes 18, 15, 10
and 8. Both single-locus and haplotype association analyses indicated
that MBD2 gene loci (rs8094493, rs4041245 and rs7614) conferred
protection against breast cancer. The magnitude and the direction of
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European Journal of Human Geneticsthe association signals in both stages were consistent between allelic
and genotypic models (Table 2). The allelic risk effects were enriched
in combined analysis with stronger association of P-values of o10 3.
Low FDR values and permutation testing provided further conﬁdence
in our ﬁndings by ruling out the observations as false positives.
Mechanistic relationships to breast carcinogenesis are suggested
because MBD2 is a well-characterized gene and the encoded protein
binds to methylated promoter regions and mediates transcriptional
repression of tumor suppressor genes.33 DNA (cytosine-5)-methyl-
transferase 1 (DNMT1) is reported to interact with the methyl-CpG-
binding protein complex, MBD2 and MBD3 at late S-phase replication
foci, and as such these interactions may direct DNMT1 to hemi-
methylated sequences following DNA replication and silencing of
genes in the S phase.34
Earlier, Zhu et al35 reported the associations of two SNPs
(rs1259938 and rs609791) in MBD2 gene regions with the reduced
risk of breast cancer in premenopausal Caucasian women.35 We
evaluated for possible LD between the distinct MBD2 SNPs reported
here and those reported by Zhu et al.35 The polymorphisms reported
by earlier investigators were not in LD with the SNPs reported here
(Figure 1a). The notable differences between our study and those by
Zhu et al35 are (i) the SNPs rs1259938 and rs609791 in the previous
study did not show association with the breast cancer phenotype in
unstratiﬁed cases, although they showed statistical signiﬁcance when
cases were stratiﬁed by pre- and postmenopausal status; (ii) we
identiﬁed distinct MBD2 gene SNPs and these were all statistically
signiﬁcantly associated with breast cancer as a phenotype even in both
unstratiﬁed (Table 2) and stratiﬁed cases (Table 3); and (iii) sample
sizes were substantially larger in our study (total sample size of 1480
cases and 1615 controls) as opposed to 393 cases and 436 controls
from the nested case–control study with a Caucasian population
reported by Zhu et al.35 In summary, observations with a larger
sample size (this study) showed association with breast cancer even
without stratiﬁcation of cases, and the haplotypes associated were also
distinct. However, it is important to note that the magnitude and
direction of risk and the gene identiﬁed are similar in both studies. We
did not genotype the polymorphisms reported by Zhu et al35 at this
time, and may therefore require independent validation. The
SNPs analyzed by Zhu et al35 were not present in the Affymetrix
SNP 6.0 array.
Other genes/loci were identiﬁed for breast cancer risk in this study.
rs2297381 was located in intron 5 of RPAP1 and was associated with
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Figure 1 Pairwise LD proﬁles between SNPs from MBD2 gene region. (a) LD proﬁle of whole MBD2 isoform 1 spanning B70.58kbp. The gene is in reverse
orientation (3¢–5¢) on chromosome 18q arm. Five SNPs (three from our study that shown in black and two from Zhu et al35 that are shown in red) in MBD2
gene regions are shown based on their relative position on HapMap CEU data set (phase 1 and 2-full data set). LD blocks were deﬁned using ‘CI’ method as
explained by Gabriel et al.42 D¢ values are given for LD between the markers. The darker the cell, the greater the D¢ value between the SNPs. (b)L Dp r o ﬁ l e
for three MBD2 SNPs from our study based on our study population.
Table 4 Haplotypes for three MBD2 SNPs and their associations with breast cancer risk
Haplotype Frequency
rs4041245 rs8094493 rs7614 Cases Controls Total OR 95% CI P-value
T A T 0.601 0.5624 0.5823 1 — —
C G G 0.385 0.4232 0.4053 0.86 0.77–0.95 0.0029
*** R a r e ( o1%) Rare (o1%) 0.0124 1.11 0.70–1.78 0.66
*Denotes alleles forming the rare haplotypes (o1% frequency).
P-value shown in bold indicates statistically signiﬁcant association at alpha, 0.05.
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European Journal of Human Geneticsthe risk of breast cancer. RPAP1 is a poorly understood gene possibly
involved in the interaction of RNA polymerase II and its regulators of
protein complex formation.36 To our knowledge, this is the ﬁrst report
on RPAP1 gene SNP associated with breast cancer risk. rs13250873
and rs1556459, located B52kbp downstream of RAD21 and
B454kbp upstream of MGMT, respectively, were signiﬁcantly asso-
ciated with the risk of breast cancer across both stages and in
combined analysis. Both RAD21 and MGMT are well-studied genes
with signiﬁcant roles in carcinogenesis. The RAD21 protein is involved
in double-strand breaks repair as well as chromatid cohesion during
mitosis.37,38 Intronic polymorphisms in RAD21 gene have been
associated with breast cancer in high-risk population.39 Similarly,
MGMT repairs the alkylated guanine due to carcinogenic effects
induced by alkylating agents.40 Coding SNPs of MGMT gene are
reported to be associated with breast cancer risk.41 MGMT SNP
reported in this study is B454kb upstream of the MGMT gene.
Although rs13250873 and rs1556459 were not located in the gene
regions, further replication of these ﬁndings and ﬁne mapping of these
loci are required to determine whether the identiﬁed polymorphisms
exert their action through regulation of the nearby RAD21 and
MGMT genes.
None of the associations reached genome-wide signiﬁcance level in
this two-stage association study with the combined sample size of
1480 cases and 1635 controls. However, conﬁdence in the reported
associations stems from the stringent quality control parameters
employed (498% SNP and sample call rates, HWE P40.001 in
controls and 498% SNP concordance in replicates and good call rate
concordance across platforms). Furthermore, the low FDR values and
results from permutation testing should favor considering the
reported polymorphisms for replication in independent studies. In
summary, we identiﬁed additional breast cancer susceptibility loci in
Caucasian women by focusing on genes related to DNA repair,
modiﬁcations and metabolism. Our study supports the concept of
investigating moderate association signals from stage 1 GWAS using a
candidate gene approach restricted to speciﬁc pathway-related gene
polymorphisms. In this study, we did not consider all related DNA
repair/modiﬁcations/metabolism pathway gene polymorphisms or
their potential associations with other subtypes of breast cancer
(basal, HER2+ and luminal B) due to limitations in sample size.
Other reported DNA repair/modiﬁcations/metabolism gene poly-
morphisms (which did not reach genome-wide signiﬁcance) in pre-
viously published studies, if replicated in independent cohorts, should
also be considered along with the six reported variants here as putative
candidates for epistatic models to gain insights to the missing
heritability of sporadic breast cancer.
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